JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M503111200 on August 26, 2005

J. Biol. Chem., Vol. 280, Issue 43, 36529-36540, October 28, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/43/36529    most recent
M503111200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pulukuri, S. M.
Right arrow Articles by Rao, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pulukuri, S. M.
Right arrow Articles by Rao, J. S.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

RNA Interference-directed Knockdown of Urokinase Plasminogen Activator and Urokinase Plasminogen Activator Receptor Inhibits Prostate Cancer Cell Invasion, Survival, and Tumorigenicity in Vivo*

Sai MuraliKrishna Pulukuri{ddagger}, Christopher S. Gondi{ddagger}, Sajani S. Lakka{ddagger}, Aman Jutla{ddagger}, Norman Estes§, Meena Gujrati¶, and Jasti S. Rao{ddagger}||1

From the {ddagger}Departments of Biomedical and Therapeutic Sciences (Program of Cancer Biology), §Surgery, Pathology, and ||Neurosurgery, University of Illinois College of Medicine, Peoria, Illinois 61656

The invasive ability of tumor cells plays a key role in prostate cancer metastasis and is a major cause of treatment failure. Urokinase plasminogen activator-(uPA) and its receptor (uPAR)-mediated signaling have been implicated in tumor cell invasion, survival, and metastasis in a variety of cancers. This study was undertaken to investigate the biological roles of uPA and uPAR in prostate cancer cell invasion and survival, and the potential of uPA and uPAR as targets for prostate cancer therapy. uPA and uPAR expression correlates with the metastatic potential of prostate cancer cells. Thus, therapies designed to inhibit uPA and uPAR expression would be beneficial. LNCaP, DU145, and PC3 are prostate cancer cell lines with low, moderate, and high metastatic potential, respectively, as demonstrated by their capacity to invade the extracellular matrix. In this study we utilized small hairpin RNAs (shRNAs), also referred to as small interfering RNAs, to target human uPA and uPAR. These small interfering RNA constructs significantly inhibited uPA and uPAR expression at both the mRNA and protein levels in the highly metastatic prostate cancer cell line PC3. Our data demonstrated that uPA-uPAR knockdown in PC3 cells resulted in a dramatic reduction of tumor cell invasion as indicated by a Matrigel invasion assay. Furthermore, simultaneous silencing of the genes for uPA and uPAR using a single plasmid construct expressing shRNAs for both uPA and uPAR significantly reduced cell viability and ultimately resulted in the induction of apoptotic cell death. RNA interference for uPA and uPAR also abrogated uPA-uPAR signaling to downstream target molecules such as ERK1/2 and Stat 3. In addition, our results demonstrated that intratumoral injection with the plasmid construct expressing shRNAs for uPA and uPAR almost completely inhibited established tumor growth and survival in an orthotopic mouse prostate cancer model. These findings uncovered evidence of a complex signaling network operating downstream of uPA-uPAR that actively advances tumor cell invasion, proliferation, and survival of prostate cancer cells. Thus, RNA interference-directed targeting of uPA and uPAR is a convenient and novel tool for studying the biological role of the uPA-uPAR system and raises the potential of its application for prostate cancer therapy.


Received for publication, March 21, 2005 , and in revised form, August 3, 2005.

* This work was supported by NCI Grants CA75557, CA85216, CA92393, CA95058, and CA116708 and NINDS Grant NS47699 from the National Institutes of Health, The William E. McElroy Foundation, Caterpillar, Inc., and OSF Saint Francis Medical Center, Peoria, IL (to J. S. R.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom correspondence should be addressed: Dept. of Biomedical and Therapeutic Sciences, Box 1649, Peoria, IL 61656. Tel.: 309-671-3445; Fax: 309-671-3442; E-mail: jsrao{at}uic.edu.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Am. J. Pathol.Home page
J. Abdulghani, L. Gu, A. Dagvadorj, J. Lutz, B. Leiby, G. Bonuccelli, M. P. Lisanti, T. Zellweger, K. Alanen, T. Mirtti, et al.
Stat3 Promotes Metastatic Progression of Prostate Cancer
Am. J. Pathol., June 1, 2008; 172(6): 1717 - 1728.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. M. K. Pulukuri, B. Gorantla, and J. S. Rao
Inhibition of Histone Deacetylase Activity Promotes Invasion of Human Cancer Cells through Activation of Urokinase Plasminogen Activator
J. Biol. Chem., December 7, 2007; 282(49): 35594 - 35603.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. Du, H. Leung, K.M. F. Khan, C. G. Miller, K. Subbaramaiah, D. J. Falcone, and A. J. Dannenberg
Tobacco Smoke Induces Urokinase-Type Plasminogen Activator and Cell Invasiveness: Evidence for an Epidermal Growth Factor Receptor Dependent Mechanism
Cancer Res., September 15, 2007; 67(18): 8966 - 8972.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. M. K. Pulukuri and J. S. Rao
Small Interfering RNA Directed Reversal of Urokinase Plasminogen Activator Demethylation Inhibits Prostate Tumor Growth and Metastasis
Cancer Res., July 15, 2007; 67(14): 6637 - 6646.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
H. Kohno, N. Takahashi, T. Shinohara, T. Ooie, K. Yufu, M. Nakagawa, H. Yonemochi, M. Hara, T. Saikawa, and H. Yoshimatsu
Receptor-Mediated Suppression of Cardiac Heat-Shock Protein 72 Expression by Testosterone in Male Rat Heart
Endocrinology, July 1, 2007; 148(7): 3148 - 3155.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. Kong, Y. Li, Z. Wang, S. Banerjee, and F. H. Sarkar
Inhibition of Angiogenesis and Invasion by 3,3'-Diindolylmethane Is Mediated by the Nuclear Factor-{kappa}B Downstream Target Genes MMP-9 and uPA that Regulated Bioavailability of Vascular Endothelial Growth Factor in Prostate Cancer
Cancer Res., April 1, 2007; 67(7): 3310 - 3319.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. Li, C. S. Gondi, D. H. Dinh, W. C. Olivero, M. Gujrati, and J. S. Rao
Transfection with Anti-p65 Intrabody Suppresses Invasion and Angiogenesis in Glioma Cells by Blocking Nuclear Factor-{kappa}B Transcriptional Activity
Clin. Cancer Res., April 1, 2007; 13(7): 2178 - 2190.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. M. K. Pulukuri, N. Estes, J. Patel, and J. S. Rao
Demethylation-Linked Activation of Urokinase Plasminogen Activator Is Involved in Progression of Prostate Cancer
Cancer Res., February 1, 2007; 67(3): 930 - 939.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
J.-S. Annicotte, I. Iankova, S. Miard, V. Fritz, D. Sarruf, A. Abella, M.-L. Berthe, D. Noel, A. Pillon, F. Iborra, et al.
Peroxisome Proliferator-Activated Receptor {gamma} Regulates E-Cadherin Expression and Inhibits Growth and Invasion of Prostate Cancer.
Mol. Cell. Biol., October 1, 2006; 26(20): 7561 - 7574.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
R. P Singh and R. Agarwal
Mechanisms of action of novel agents for prostate cancer chemoprevention.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 751 - 778.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Gardsvoll, B. Gilquin, M. H. Le Du, A. Menez, T. J. D. Jorgensen, and M. Ploug
Characterization of the Functional Epitope on the Urokinase Receptor: COMPLETE ALANINE SCANNING MUTAGENESIS SUPPLEMENTED BY CHEMICAL CROSS-LINKING
J. Biol. Chem., July 14, 2006; 281(28): 19260 - 19272.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Alfano, I. Iaccarino, and M. P. Stoppelli
Urokinase Signaling through Its Receptor Protects against Anoikis by Increasing BCL-xL Expression Levels
J. Biol. Chem., June 30, 2006; 281(26): 17758 - 17767.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. A. Madsen, E. I. Deryugina, S. Niessen, B. F. Cravatt, and J. P. Quigley
Activity-based Protein Profiling Implicates Urokinase Activation as a Key Step in Human Fibrosarcoma Intravasation
J. Biol. Chem., June 9, 2006; 281(23): 15997 - 16005.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.